Synthaverse (SVE) Stock Overview
A pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.53 |
| 52 Week High | zł5.91 |
| 52 Week Low | zł3.51 |
| Beta | 0.040 |
| 1 Month Change | -9.95% |
| 3 Month Change | -20.05% |
| 1 Year Change | -14.73% |
| 3 Year Change | -36.40% |
| 5 Year Change | -56.85% |
| Change since IPO | -26.46% |
Recent News & Updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is Lacking
May 20
Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 28Recent updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is Lacking
May 20Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 28Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly
Oct 14More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%
Nov 29We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings
Nov 16Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?
May 02Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?
Mar 08What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?
Jan 29
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 03BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt
Dec 07Shareholder Returns
| SVE | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -4.6% | -1.2% | 1.7% |
| 1Y | -14.7% | -2.2% | 38.0% |
Return vs Industry: SVE underperformed the Polish Biotechs industry which returned -2.9% over the past year.
Return vs Market: SVE underperformed the Polish Market which returned 38.3% over the past year.
Price Volatility
| SVE volatility | |
|---|---|
| SVE Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 9.0% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: SVE has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: SVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 239 | Mieczyslaw Starkowicz | synthaverse.com |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines.
Synthaverse S.A. Fundamentals Summary
| SVE fundamental statistics | |
|---|---|
| Market cap | zł249.82m |
| Earnings (TTM) | zł4.45m |
| Revenue (TTM) | zł62.66m |
Is SVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVE income statement (TTM) | |
|---|---|
| Revenue | zł62.66m |
| Cost of Revenue | zł24.58m |
| Gross Profit | zł38.08m |
| Other Expenses | zł33.63m |
| Earnings | zł4.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.063 |
| Gross Margin | 60.77% |
| Net Profit Margin | 7.10% |
| Debt/Equity Ratio | 71.9% |
How did SVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/23 02:01 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.